ADVICENNE (ALDVI.PA) Stock Price, Forecast & Analysis
Europe • Euronext Paris • EPA:ALDVI • FR0013296746
ALDVI.PA Key Statistics, Chart & Performance
The current stock price of ALDVI.PA is 1.674 EUR. In the past month the price decreased by -10.1%. In the past year, price decreased by -16.51%.
ALDVI.PA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ALDVI.PA. When comparing the yearly performance of all stocks, ALDVI.PA is a bad performer in the overall market: 81.88% of all stocks are doing better.
ALDVI.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALDVI.PA. Both the profitability and financial health of ALDVI.PA have multiple concerns.
ALDVI.PA Financial Highlights
Over the last trailing twelve months ALDVI.PA reported a non-GAAP Earnings per Share(EPS) of -0.53. The EPS increased by 14.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -96.03% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALDVI.PA Forecast & Estimates
9 analysts have analysed ALDVI.PA and the average price target is 4.08 EUR. This implies a price increase of 143.73% is expected in the next year compared to the current price of 1.674.
For the next year, analysts expect an EPS growth of 17.08% and a revenue growth 54.05% for ALDVI.PA
ALDVI.PA Ownership
About ALDVI.PA
Company Profile
Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Paris, Ile-De-France and currently employs 15 full-time employees. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
Company Info
ADVICENNE
262, Rue du Faubourg Saint Honore
Paris ILE-DE-FRANCE FR
Employees: 21
Phone: 33185733620
ADVICENNE / ALDVI.PA FAQ
What does ADVICENNE do?
Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Paris, Ile-De-France and currently employs 15 full-time employees. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
Can you provide the latest stock price for ADVICENNE?
The current stock price of ALDVI.PA is 1.674 EUR. The price decreased by -0.95% in the last trading session.
Does ADVICENNE pay dividends?
ALDVI.PA does not pay a dividend.
What is the ChartMill rating of ADVICENNE stock?
ALDVI.PA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
When does ADVICENNE (ALDVI.PA) report earnings?
ADVICENNE (ALDVI.PA) will report earnings on 2026-03-25, after the market close.
What is the ownership structure of ADVICENNE (ALDVI.PA)?
You can find the ownership structure of ADVICENNE (ALDVI.PA) on the Ownership tab.